zbMATH — the first resource for mathematics

Two-stage winner designs for non-inferiority trials with pre-specified non-inferiority margin. (English) Zbl 1357.62269
Summary: In drug development, a two-stage winner design [K. K. G. Lan et al., in: Random walk, sequential analysis and related topics. A Festschrift in honor of Yuan-Shih Chow. Papers presented at the international conference, Shanghai, China, July 18–19, 2004. Hackensack, NJ: World Scientific. 28–43 (2006; Zbl 1158.62050); Z. Shun et al., “Interim treatment selection using the normal approximation approach in clinical trials”, Stat. Med. 27, No. 4, 597–618 (2008; doi:10.1002/sim.2990)] can be cost-effective when the best treatment is to be determined from multiple experimental treatments in superiority trials. However, the statistical methods assessing non-inferiority in a two-stage winner design have not yet been studied, for which the complexity arises in determining the critical value when parameter space is not a single point under the null hypothesis. Because the maximum error may not occur at the vertex of the null space, it is unclear if naive use of critical values and distributional results from the test for superiority remains correct. In this paper, we provided rigorous justifications to determine the critical value for testing non-inferiority hypothesis, with a pre-specified non-inferiority margin, in a two-stage winner design with two experimental treatments and an active control. We studied the distribution of the test statistics, critical values, sample size and power calculations using the exact distribution of the test statistics as well as using normal approximations. Theoretical justifications and extensive numerical assessments were conducted to calculate the design parameters and evaluate the performance of our methods.
62L10 Sequential statistical analysis
62L05 Sequential statistical design
62P10 Applications of statistics to biology and medical sciences; meta analysis
Full Text: DOI
[1] Bauer, P.; Kieser, M., Combining different phases in the development of medical treatments within a single trial, Stat. Med., 18, 1833-1848, (1999)
[2] Brown, D. M.; Kaiser, P. K.; Michels, M.; Soubrane, G.; Heier, J. S.; Kim, R. Y.; Sy, J. P.; Schneider, S., Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N. Engl. J. Med., 355, 1432-1444, (2006)
[3] Chia, G. Y.H.; Liu, Q., The attractiveness of the concept of a prospectively designed two-stage clinical trial, J. Biopharm. Statist., 9, 537-547, (1999) · Zbl 1056.62538
[4] Fang, F.; Lin, Y.; Shih, W. J.; Li, Y.; Yangd, J.; Zhange, X., Methods of designing two-stage winner trials with survival outcomes, Stat. Med., 33, 1539-1563, (2014)
[5] Genentech USA, 2008. Lucentis^®(ranibizumab injection) prescribing information.
[6] Hommel, G., Adaptive modifications of hypotheses after an interim analysis, Biom. J., 43, 581-589, (2001) · Zbl 1029.62083
[7] Lan, K. G.; Soo, Y.; Shun, Z., Normal approximation for two-stage winner design, 28-43, (2005), World Scientific · Zbl 1158.62050
[8] Li, G.; Wang, Y.; Ouyang, S. P., Interim treatment selection in drug development, Stat. Biosci., 1, 268-288, (2009)
[9] Maca, J., Adaptive seamless phase ii/iii designs-background, operational aspects, and examples, Drug Inf. J., 40, 463-474, (2006)
[10] Muller, H.; Schafer, H., A general statistical principle for changing a design any time during the course of a trial, Stat. Med., 23, 2497-2508, (2004)
[11] Posch, M.; Koening, F.; Branson, M.; Brannath, W.; Dunger-Baldaul, C.; Bauer, P., Testing and estimation in flexible group sequential designs with adaptive treatment selection, Stat. Med., 24, 3697-3714, (2005)
[12] Rosenfeld, P. J.; Brown, D. M.; Heier, J. S.; Boyer, D. S.; Kaiser, P. K.; Chung, C. Y.; Kim, R. Y., Ranibizumab for neovascular age-related macular degeneration, N. Engl. J. Med., 355, 1419-1431, (2006)
[13] Sampson, A.; Sill, M., Drop-the-loser design: normal case, Biom. J., 47, 257-268, (2005)
[14] Shun, Z.; Lan, K. G.; Soo, Y., Interim treatment selection using the normal approximation approach in clinical trials, Stat. Med., 27, 597-618, (2008)
[15] Stallard, N.; Todd, S., Sequential designs for phase iii clinical trials incorporating treatment selection, Stat. Med., 22, 689-703, (2003)
[16] Thall, P. F.; Simon, R.; Ellenberg, S. S., Two-stage selection and testing designs for comparative clinical trials, Biometrika, 75, 303-310, (1988) · Zbl 0639.62096
[17] Thall, P. F.; Simon, R.; Ellenberg, S. S., A two-stage design for choosing among several experimental treatments and a control in clinical trials, Biometrics, 45, 537-547, (1989) · Zbl 0715.62239
[18] Todd, S.; Stallard, N., A new clinical trial design combining phase 2 and 3: sequential designs with treatment selection and a change of endpoint, Drug Inf. J., 39, 109-118, (2005)
[19] Wang, Y.; Lan, K. G.; Li, G.; Ouyang, S. P., A group sequential procedure for interim treatment selection, Stat. Biopharm. Res., 3, 1-13, (2011)
[20] Wu, Y.; Zhao, P., Interim treatment selection with a flexible selection margin in clinical trials, Stat. Med., 32, 2529-2543, (2012)
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. It attempts to reflect the references listed in the original paper as accurately as possible without claiming the completeness or perfect precision of the matching.